Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$319.56 USD

319.56
307,956

+5.34 (1.70%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

STERIS (STE) AST Business Expands, New Offerings Aid Growth

by Zacks Equity Research

STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

by Zacks Equity Research

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

by Zacks Equity Research

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

Thermo Fisher (TMO) to Open New NanoPort Facility in Taiwan

by Zacks Equity Research

Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region???s semiconductor manufacturing hub.

Thermo Fisher (TMO) Strategic Buyouts Aid Amid Macro Issues

by Zacks Equity Research

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

by Zacks Equity Research

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership

by Zacks Equity Research

QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

by Zacks Equity Research

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

by Zacks Equity Research

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

by Zacks Equity Research

Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.

Should You Hold STERIS (STE) Stock Now? Here's What to Consider

by Zacks Equity Research

STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues

by Zacks Equity Research

Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.

Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial

by Zacks Equity Research

Neogen (NEOG) instills optimism among investors with its strategic progress and a string of product launches.

Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio

by Zacks Equity Research

Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY

by Zacks Equity Research

Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.

Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout

by Zacks Equity Research

By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.

Omnicell (OMCL) Banks on Product Launches, Global Growth

by Zacks Equity Research

Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.

Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs

by Zacks Equity Research

Thermo Fisher (TMO) has launched biobased solutions to help reduce the climate impact on the manufacturing of therapies.

Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab

by Zacks Equity Research

Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.

Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

by Zacks Equity Research

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?

by Zacks Equity Research

Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.

National Vision (EYE) Gains Market Share Despite Macro Woes

by Zacks Equity Research

National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.

Thermo Fisher (TMO) Expands Central Lab Footprint in Kentucky

by Zacks Equity Research

Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.

Community Health (CYH) & Cost Plus Drugs Expand Collaboration

by Zacks Equity Research

Community Health (CYH) is now set to source drugs from the Cost Plus Drugs Marketplace under the new expanded partnership.